GSK, the world's largest vaccine maker by sales, has been under pressure to shore up its pipeline. Last month, it indicated an appetite for further deals after spending $1.9 billion to buy Sierra Oncology to bolster its cancer business. GSK pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax to bolster its vaccine pipeline, a key area of focus as the British drugmaker prepares to separate its consumer unit. GSK, the world's largest vaccine maker by sales, has been under pressure to shore up its pipeline. Last month, it indicated an appetite for further deals after spending $1.9 billion to buy Sierra Oncology to bolster its cancer business. U.S.-based Affinivax is developing next-generation vaccines, the company said, the most advanced of which are for pneumococcal diseases, including pneumonia, meningitis and sinusitis. GSK will pay Affinivax $2.1 billion upfront and up to $1.2 billion in potential development milestones. The London-listed company on Tuesday also reiterated its outlook for 2022 and its medium-term targets.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!